-
"Double wheel" drives the group's "dye blue" index, and the first "breakthrough" consistency evaluation of three varieties seizes nearly 10 billion market
Time of Update: 2018-06-13
On June 4, Shijiazhuang Pharmaceutical Group officially joined the "blue chips" of Hong Kong Hang Seng Index and was crowned the "first pharmaceutical share" of Hang Seng Index On the same day, the gr
-
R & D is worth nearly 5 billion yuan a year! How good are the three major products of domestic pharmaceutical enterprises?
Time of Update: 2018-06-12
The R & D expenses of listed pharmaceutical companies with wonderful contents have always been one of the focuses of the public According to statistics, the R & D expenses of Hengrui pharmaceutical, C
-
The market of large varieties of traditional Chinese medicine injection is in crisis. How about the progress of enterprise re evaluation?
Time of Update: 2018-06-12
On June 11, the State Food and Drug Administration issued a notice, deciding to revise the instructions of Shuanghuanglian injection (Shuanghuanglian injection, Shuanghuanglian for injection (freeze d
-
50 billion market! Fuhong Hanlin, Xinda, Hengrui The first shot of Chinese biological analogues?
Time of Update: 2018-06-11
The continuous investment of human capital, the acceleration of examination and approval, and the gradual clarity of the registration path will become the fundamental driving force for the explosive g
-
Three domestic pharmaceutical companies are leading the 10 billion market of psychotranquilizers, and 12 class 1 new drugs are under development
Time of Update: 2018-06-08
On May 25, Enhua pharmaceutical released a notice that the company's chemical product class 1, zilonapine succinate tablet and its API have received CFDA's notice on acceptance of clinical trials of n
-
Injection consistency evaluation is about to break out, 600 billion market turbulence, 11 over 1 billion varieties, who do you like best?
Time of Update: 2018-06-07
Highlights on June 4, the State Food and Drug Administration issued the 2018 drug tracking and inspection plan, and decided to track and inspect 201 drug manufacturers, 60 of which were newly approved
-
How far is GPCR antibody new drug from 0 to 1?
Time of Update: 2018-06-06
Archimedes has a famous saying, "give me a fulcrum, I can move the earth." If someone brings this confidence to the pharmaceutical field and says, "give me a target, I can successfully develop a new d
-
Deep Guangpo cut another 30 kinds of drug prices! Shiguibao, Lilai, YANGSEN, etc
Time of Update: 2018-06-06
On June 5, quanyao.com released the notice on publicizing the price reduction of some traded varieties in the purchase catalogue of Shenzhen Public Hospital Pharmaceutical Group and the notice on publ
-
Hengrui, Junshi, Xinda and Baiji are competing for supremacy, and the first echelon of PD-1 market is competing for listing!
Time of Update: 2018-06-05
Hengrui PD-1 is the fifth McAb applying for listing in China BMS, MSD, Junshi and Cinda have submitted listing applications before it The first echelon of domestic PD-1 has been formed On April 23, 20
-
"Billion regiment" adds the formidable general again! In half a year, 9 class 1 new drugs have been approved for clinical application, 4 anda. Why is Hengrui so good at R & D?
Time of Update: 2018-06-05
Brilliant content a few days ago, Hengrui pharmaceutical announced that the company has received the new drug certificate and drug registration approval document of thiopefigeristine injection (19K) i
-
Who leads the market of 70 billion children's drugs
Time of Update: 2018-06-04
According to the latest 2017 national economic and Social Development Statistics Bulletin released by the National Bureau of statistics on February 28, 2018, the number of 0-15-year-old children in Ch
-
Competitive pattern of insulin and GLP-1 receptor agonists in China
Time of Update: 2018-06-04
According to IDF statistics, in 2017, there were 425 million diabetics in the world, including 114 million in China, accounting for about 25% of the world, ranking first in the world Although the insu
-
The first new hepatitis C drug was approved! The market war of foreign enterprises started, followed by Geli
Time of Update: 2018-06-01
Propionoxar (suzophtbuvir 400 mg / vpatavir 100 mg) has been approved by the National Drug Administration for the treatment of adult patients with gene 1-6 chronic hepatitis C virus (HCV) infection, G
-
Forbes is the most innovative company in the world. It is the only Chinese pharmaceutical company! Why?
Time of Update: 2018-05-31
In addition to Hengrui pharmaceutical which has been listed in the list for years, who will be the next innovative Chinese pharmaceutical enterprise? On May 28, 2018, the world's 100 most innovative c
-
Summary of class 1 PD-1 drugs on the market and drugs under research in China
Time of Update: 2018-05-31
PD-1 (programmed cell death protein 1) is an important immunosuppressive molecule It is a member of CD28 superfamily It was originally cloned from the apoptotic mouse T-cell hybridoma 2b4.11 PD-1 as t
-
A closer look at the domestic anti-tumor drug market: the main varieties of sample hospitals and the sales performance of monoclonal antibodies and TiNi
Time of Update: 2018-05-30
At present, cancer and other diseases have become the main cause of death in China, and cancer mortality remains high, which has become a major social issue of concern In this context, the global anti
-
Second liver market kills novice, market pattern will change? Multiple pharmaceutical companies accelerate the layout
Time of Update: 2018-05-30
This is a potential market segment, and the previous competition is not fierce However, from the perspective of the competitive layout of various enterprises, the market pattern is changing A group of
-
Chinese pharmaceutical companies challenge the global TOP10 tumor drugs! Who are the real gold nuggets, such as Hengrui, Fosun, and Kelun?
Time of Update: 2018-05-29
This is a huge market with RMB over 100 billion Under the trend of clear policy, who can seize the opportunity, who is the real gold digger in the future When Chinese patients buy prescription drugs across the border, it's back on the table!
-
Since May 30, the nine price HPV vaccine can be injected in Hainan. How is the research and development progress of domestic enterprises?
Time of Update: 2018-05-28
According to Hainan Daily, from May 30, the United Family Medical Center of Boao super hospital can be injected with a nine valent HPV vaccine to prevent cervical cancer The injectable age was 16-26 y
-
Multinational pharmaceutical company PD-1 faces localization challenges in China
Time of Update: 2018-05-24
There is a long way to go to fully understand the mechanism of PD-1 / PD-L1 pathway At present, how to make the best use of PD-L1 expression as a biomarker of immunotherapy prognosis has caused a lot
